In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on ATAI Life Sciences (ATAI – Research Report). The company’s shares closed yesterday at $1.30.

Baral covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Insmed, and Neurogene. According to TipRanks, Baral has an average return of 7.4% and a 44.06% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for ATAI Life Sciences with a $11.00 average price target.

The company has a one-year high of $2.85 and a one-year low of $1.03. Currently, ATAI Life Sciences has an average volume of 1.17M.

Based on the recent corporate insider activity of 10 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATAI in relation to earlier this year.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

ATAI Life Sciences (ATAI) Company Description:

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKporJRisLDDxKdkrKyZmLi0edOoZKKso2KvtsWMq5itoZ6ceqe70WaYrZmZYrmqssRmqpyhlaOwpr%2BMmquaoV1mfXR%2FlGtubWpk